Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects

Participants who developed anti-drug antibodies after treatment with Etanercept were evaluated. Percentage of participants with positive Etanercept anti-drug antibodies were summarized.

Time frame: Week 12

Population: Analysis set included all participants who had taken at least 1 dose of study medication and had at least 1 Etanercept anti-drug antibody evaluation. Here, Number of Participants Analyzed (N) signifies number of participants evaluable for this outcome measure.

Participants who developed anti-drug antibodies after treatment with Etanercept were evaluated. Percentage of participants with positive Etanercept anti-drug antibodies were summarized.

Time frame: Week 24

Population: Analysis set included all participants who had taken at least 1 dose of study medication and had at least 1 Etanercept anti-drug antibody evaluation. Here, N signifies number of participants evaluable for this outcome measure.

Participants who developed anti-drug antibodies after treatment with Etanercept were evaluated. Percentage of participants with positive Etanercept anti-drug antibodies were summarized.

Time frame: Baseline up to Week 24

Population: Analysis set included all participants who had taken at least 1 dose of study medication and had at least 1 Etanercept anti-drug antibody evaluation.

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from the number of swollen joints and tender joints using the 28 joints count, C-Reactive protein (milligram per liter \[mg/L\]) and participant's general health visual analog scale assessment (scores ranging 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 10 (extreme disease activity), higher scores indicate more disease activity. DAS28-4 (CRP) less than (\<) 2.6= remission, \<3.2= low disease activity, greater than or equal to (\>=) 3.2 to 5.1= moderate disease activity and \>5.1= high disease activity.

Time frame: Baseline, Week 4, 12, 24

Population: mITT population included all participants who had taken at least 1 dose of study medication. Here, n signifies number of participants who were evaluable for specified time points.

DAS28: measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from number of swollen joints (SJC) and tender joints (TJC ) using the 28 joints count, erythrocyte sedimentation rate (millimeter per hour \[mm/hour\]) and participant's general health visual analog scale assessment (scores: 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score: 0 (none) to 10 (extreme disease activity), higher scores indicate more disease activity. DAS28-4 (ESR) less than (\<) 2.6= remission, \<3.2= low disease activity, greater than or equal to (\>=) 3.2 to 5.1= moderate disease activity and \>5.1= high disease activity.

Time frame: Baseline, Week 4, 12, 24

Population: mITT population included all participants who had taken at least 1 dose of study medication. Here, n signifies number of participants who were evaluable for specified time points.

HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each item scored on 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

Time frame: Baseline, Week 4, 12, 24

Population: mITT population included all participants who had taken at least 1 dose of study medication. Here, n signifies number of participants who were evaluable for specified time points.

Laboratory abnormalities(national cancer institute toxicity criteria version 4.0),Grade 3:neutrophil (greater than or equal to\[\>=\]0.5,less than\[\<\]1.0 10\^9/L),lymphocyte (\<0.5 10\^9/L),hemoglobin (Hb) (\<80,\>=65 gram per liter \[g/L\]),platelet(\<50.0,\>=25.0 10\^9/L),white blood count(WBC) (\<2.0, \>=1.0 10\^9/L);alkaline phosphatase (AP),aspartate aminotransferase(AST),alanine aminotransferase(ALT) (greater than\[\>\]5.0\*upper range \[UR\], \<=20.0\*UR unit per liter\[U/L\]);bilirubin(\>1.5\*UR, less than or equal to\[\<=\]3.0\*UR micromole per liter\[mcmol/L\]);creatinine(\>3.0\*UR, \<=6.0\*UR mcmol/L);albumin (\<20.0 g/L),urea(\>3.0\*UR, \<=4.0\*UR g/L);potassium (K)-high,low (\>6.0,\<=7.0or\<3.0,\>=2.5 mcmol/L); sodium(Na)-high,low(\>155, \<=160 or \<130, \>=120 mcmol/L)and Grade 4: neutrophil(\<0.5 10\^9/L),Hb (\<65 g/L);platelet (\<25.0 10\^9/L); WBC(\<1.0 10\^9/L);AP,AST,ALT(\>20.0\*UR U/L);bilirubin(\>3.0\*UR mcmol/L);creatinine (\>6.0\*UR mcmol/L);urea (\>4.0\*UR g/L);K-high,low (\>7.0or\<2.5 mcmol/L);Na-high, low (\>160or\<120 mcmol/L).

Time frame: Baseline (Day 1) up to Week 28 (Follow-up)

Population: Safety population included all participants who had taken at least 1 dose of study medication.

Injection site reactions included injection site erythema, swelling, pain and warmth.

Time frame: Baseline (Day 1) up to Week 28 (Follow-up)

Population: Safety population included all participants who had taken at least 1 dose of study medication.

Infection was considered as serious by investigator for any of the following outcomes: death; life-threatening; required initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity or congenital anomaly/birth defect.

Time frame: Baseline (Day 1) up to Week 28 (Follow-up)

Population: Safety population included all participants who had taken at least 1 dose of study medication.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame: Baseline (Day 1) up to Week 28 (Follow-up)

Population: Safety population included all participants who had taken at least 1 dose of study medication.

ACR20 responder: participants with 20 percent (%) improvement in tender and swollen 28-joint counts and 20% improvement in at least 3 of the 5 measures: participant global assessment of arthritis (PtGA), physician global assessment of arthritis (PGA), participant pain visual analogue scale (Pain-VAS), health assessment questionnaire-disability index (HAQ-DI) and C-reactive protein. PtGA: participant assessed overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PGA: physician judged participant's overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. Pain-VAS: participant assessed arthritis pain by 100 millimeter (mm) VAS, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score=more disability. Percentage of participants with ACR20 response were reported.

Time frame: Week 4, 12, 24

Population: Modified intent-to-treat (mITT) population included all participants who had taken at least 1 dose of study medication. Here, n signifies number of participants who were evaluable for specified time points.

ACR50 responder: participants with 50% improvement in tender and swollen 28-joint counts and 50% improvement in at least 3 of the 5 measures: participant global assessment of arthritis (PtGA), physician global assessment of arthritis (PGA), participant pain visual analogue scale (Pain-VAS), health assessment questionnaire-disability index (HAQ-DI) and C-reactive protein. PtGA: participant assessed overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PGA: physician judged participant's overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. Pain-VAS: participant assessed arthritis pain by 100 millimeter (mm) VAS, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score=more disability. Percentage of participants with ACR50 response were reported.

Time frame: Week 4, 12, 24

Population: mITT population included all participants who had taken at least 1 dose of study medication. Here, n signifies number of participants who were evaluable for specified time points.

ACR70 responder: participants with 70% improvement in tender and swollen 28-joint counts and 70% improvement in at least 3 of the 5 measures: participant global assessment of arthritis (PtGA), physician global assessment of arthritis (PGA), participant pain visual analogue scale (Pain-VAS), health assessment questionnaire-disability index (HAQ-DI) and C-reactive protein. PtGA: participant assessed overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PGA: physician judged participant's overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. Pain-VAS: participant assessed arthritis pain by 100 millimeter (mm) VAS, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score=more disability. Percentage of participants with ACR70 response were reported.

Time frame: Week 4, 12, 24

Population: mITT population included all participants who had taken at least 1 dose of study medication. Here, n signifies number of participants who were evaluable for specified time points.

Percentage of participants with positive Etanercept neutralizing anti-drug antibodies were summarized.

Time frame: Baseline (Day 1) up to Week 24

Population: Analysis set included all participants who had taken at least 1 dose of study medication and had at least 1 Etanercept anti-drug antibody evaluation.